Introduction {#Sec1}
============

Abnormal cardiac and vascular structure and function play a key part in excessive cardiovascular events and premature mortality experienced by patients with end-stage renal disease using haemodialysis (HD). This cannot wholly be attributed to the high burden of atherosclerotic risk factors. Factors specific to chronic kidney disease (CKD) such as anaemia, hyperphosphatemia and vascular calcification are well-recognized to cause left ventricular dilatation and hypertrophy \[[@CR1]\]. It is also known that the HD procedure itself contributes to development of cardiomyopathy by inducing hypotension and cardiac ischemia, as detected by early transient reductions in ventricular deformation that precede global dysfunction and increased mortality. Drug-based therapies that reduce cardiovascular morbidity in the CKD population have been ineffective in those using HD \[[@CR2]\]. The development of cardiomyopathy might be prevented by early application of HD-based interventions such as cool dialysate or an extended length of HD treatment \[[@CR3], [@CR4]\].

Adverse changes in left ventricular (LV) geometry and function after cardiac injury are termed remodelling. At a cellular level, remodelling is characterised by cardiomyocyte hypertrophy, interstitial fibrosis, apoptosis and capillary rarefaction. Cardiovascular magnetic resonance (CMR) imaging is the reference standard technique for analysis of LV mass, volumes and geometry. The LV mass-to-volume ratio indexes LV wall thickness to cavity size, categorizing LV geometry as concentric remodelling, concentric hypertrophy or eccentric hypertrophy. The type of geometry has been noted to prognosticate cardiovascular risk beyond that by LV hypertrophy alone in HD patients and large general population studies \[[@CR5], [@CR6]\]. In addition, CMR images of the left ventricle (LV) can be magnetically 'tagged' with a grid pattern. The motion of these tags can be tracked by software to quantify the magnitude (strain) and velocity (strain rate) of tissue deformation, providing an earlier marker of LV dysfunction than the ejection fraction (EF) \[[@CR7]\].

Prior CMR data reported HD patients with several years of exposure to HD, using gadolinium contrast media that are now contraindicated for patients with impaired kidney function. Such studies are limited by prevalence-incidence bias which is particularly relevant as mortality within the first 6 months of starting HD is markedly increased \[[@CR8]\]. There are few studies in patients new to HD using indices that might detect abnormalities earlier, such as strain or dyssynchrony \[[@CR9]\]. We aimed to phenotype cardiac abnormalities in an unselected incident HD population with non-contrast tagged CMR to determine the characteristics and severity of HD-associated cardiomyopathy in the early phase of a patient's time using HD.

Materials and methods {#Sec2}
=====================

Subjects {#Sec3}
--------

This multi-centre study was approved by the institutional review board and conducted in accordance with the Declaration of Helsinki. All participants gave written informed consent. The HD patients were recruited from four geographically local university teaching hospitals as part of a clinical trial of an intervention to prevent cardiomyopathy, with these data acquired prior to any trial interventions. Inclusion criteria were:Age ≥16 yearsHaving HD treatment three times per week.Willing and able to provide consent.Exposure to haemodialysis for ≤180 days.

Exclusion criteria were:Contraindications for CMRInability to tolerate CMR due to claustrophobiaNew York Heart Association grade IV heart failurePregnancy or lactatingMental incapacity to consent

Healthy volunteers were recruited through a local clinical research volunteer program. Their inclusion criteria were:Age ≥16 years.Willing and able to provide consent.

Exclusion criteria were:Contraindications for CMRInability to tolerate CMR due to claustrophobiaHistory of kidney disease, heart disease or cardiomyopathyMental incapacity to consent

HD characteristics {#Sec4}
------------------

Patients were treated with in-centre HD treatments three times per week, with treatment times of 3.5--4 hours using low-flux dialyzers (LOPS 18/20; Braun Medical Ltd, Sheffield, UK). Dialysate temperature was 36--37 °C. Dialysate composition was sodium 136--138 mmol/l; potassium 2 mmol/l; calcium 1.25 mmol/l; magnesium 0.5 mmol/l; bicarbonate 32--38 mmol/l; glucose 5.6 mmol/l and acetate 3 mmol/l. Dialysate flow rate was 500 mL/min and blood pump speed was 250--450 mL/min using anticoagulation by unfractionated heparin. Dry weight was prescribed by the clinical team according to local protocol to achieve an equilibrated Kt/V~urea~ \>1.1 and standardized Kt/V~urea~ of \>2.0.

Data collection {#Sec5}
---------------

Imaging by CMR was timed on a midweek post-dialysis day avoiding the long break in dialysis after the weekend, when patients are most hypervolemic \[[@CR10]\]. Studies were conducted using a 1.5-Tesla scanner (GE Signa HDxt, GE Healthcare, Milwaukee, USA) with an 8-channel phased-array receiver coil, 12--20-second end-expiratory breath-holds and retrospective electrocardiographic (ECG) gating \[[@CR11]\]. Steady-state free precession (SSFP) cine images were acquired in 2-, 3- and 4-chamber views to plan a stack of 8-mm short-axis slices with a 2-mm interslice gap, spanning the cardiac apex through the ventricular base. Imaging parameters as detailed in Table [1](#Tab1){ref-type="table"} were optimised with a minimal field of view to achieve a typical in-plane spatial resolution \<2 mm and temporal resolution \<50 ms. Radiofrequency tagging by a spatial modulation of magnetization (SPAMM) sequence with gradient recalled-echo readout was applied at basal, mid-ventricular and apical levels, typically achieving temporal resolution \<40 ms. Multi-plane localizer images were used to plan an oblique sagittal SSFP cine of the ascending and descending aorta. An axial SSFP cine was acquired at the level of the pulmonary artery bifurcation to allow assessment of aortic distensibility. An orthogonal high temporal resolution (\<10 ms) through-plane velocity-encoded sequence was acquired to allow assessment of pulse-wave velocity.Table 1Typical CMR acquisition parametersParametersVentricular SSFP-cinesVentricular SPAMM taggingAortic SSFP-cines for distensibilityAortic velocity-encoded for PWVRespiratory compensationbreath-holdbreath-holdbreath-holdfree breathingAcquisition time (s)12--1812--1812--18240--360ECG gatingretrospectiveretrospectiveretrospectiveretrospectiveTR: repetition time (ms)3.26.73.26.7TE: echo time (ms)1.73.11.74.5Voxel size (mm)1.7 × 1.7 × 81.7 × 2.4 × 101.3 × 2.5 × 51.3 × 2.5 × 5Slice thickness (mm)81055Interslice gap (mm)26--12NANATypical field-of-view (mm)380380320320Matrix224 × 224224 × 160256 × 128256 × 128Parallel imagingenabledenabledenabledenabledView-sharingYesYesYesYesFlip angle (degrees)60126030Number of signal averages1114Lines per segment1610161Reconstructed phases303030100Temporal resolution (ms)20--5020--4020--50\<10VENC (cm/s)150--200

Body composition {#Sec6}
----------------

Volume status was assessed by segmental multiple-frequency bioelectrical impedance measurements, using tetrapolar 8-point tactile electrodes (InBody S20, Biospace, Seoul, South Korea) \[[@CR12]\]. Hypervolemia was estimated by the ratio of extracellular water to total body water \[[@CR13]\].

Biochemical markers {#Sec7}
-------------------

Serum samples for determination of high-sensitivity troponin-T and NT-proBNP were taken immediately after insertion of access needles on HD on the day preceding the CMR study. Samples were promptly centrifuged and analysed using the Elecsys 2010 system (Roche Diagnostics, Switzerland). The limits of detection of the troponin-T assay are 0.005 μg/L, the 99th percentile 0.014 μg/L and the 10 % co-efficient of variation is 0.013 μg/L \[[@CR14]\]. The limits of detection of the NT-proBNP assay is 0.6 pmol/l and the interassay co-efficient of variation is 3.9 %.

Data analysis {#Sec8}
-------------

All CMR analyses were performed offline in a blinded fashion. End-systolic and end-diastolic LV volumes and end-diastolic LV mass were determined using cvi42 software, version 4.0.2 (Circle Cardiovascular Imaging, Calgary, Canada). The LV contours were drawn manually excluding papillary muscles and trabeculations in accordance with previously validated methods proven to be more reproducible than alternative techniques \[[@CR6], [@CR15]\]. LV mass was calculated by taking the difference between the end-diastolic endocardial and epicardial volume multiplied by 1.05 g/mL, which is the density of myocardium. LV concentric remodelling was determined by the LV mass/volume ratio where a higher ratio corresponds to greater concentric remodelling. Values were indexed to body surface area using the method described by Mosteller \[[@CR16]\].

Strain analysis {#Sec9}
---------------

Tagged LV short-axis images were analysed using validated software as previously described \[[@CR17]\]. The process is depicted in Fig. [1](#Fig1){ref-type="fig"}. Peak-systolic strain (PSS), peak-systolic strain-rate (PSSR) and peak diastolic strain-rate (PDSR) were determined. The standard deviation of segmental time-to-peak strain (SD-TTP) normalised to a heart rate of 70 beats per minute was calculated as a measure of LV dyssynchrony as previously described \[[@CR18]\]. Data were analysed in the 16-segment LV model recommended by the American Heart Association and averaged per short-axis slice and across all segments to determine global LV strains \[[@CR19]\] (Fig. [1](#Fig1){ref-type="fig"}).Fig. 1LV circumferential strain analysis in a typical study participant. Tagged LV short-axis images had manual endocardial and epicardial border tracing in a single frame, with automated propagation of the contours to all other frames to generate LV segmental strain curves (*B*) recording both peak strain and the time-to-peak strain (dotted lines, *B*). Segmental strains were averaged to determine global LV strain (*C*) and strain-rate (*D*) curves from which peak-systolic and diastolic values were used as study outcomesFig. 2Determination of aortic distensibility in the same study participant as in Figure 2. An oblique sagittal image of the thoracic aorta (*A*) was used to determine the pulse-wave propagation distance (*solid line*, *A*) at the level of the right pulmonary artery (*dotted line*, *A*). Orthogonal axial SSFP cines (*B*) and velocity encoded images (*C*) were used to contour the ascending and descending aorta to derive traces of aortic area (*upper panel* in *D*) and aortic blood flow (*lower panel* in *D*) versus time. Aortic distensibility was determined by dividing the maximal area change by pulse-pressure. Aortic arch pulse wave velocity was calculated by dividing the pulse-wave propagation distance by the transit delay between these positions determined by cross-correlation of the flow velocity profiles (*lower panel* in *D*)

Aortic distensibility {#Sec10}
---------------------

The ascending and descending aortas were manually outlined with semi-automated propagation into all cardiac phases using the Jim software package (version 6, Xinapse Systems, UK). Aortic distensibility was calculated from the SSFP cines as (maximum aortic area -- minimum aortic area) / (minimum aortic area x ΔP), where ΔP is the average of three brachial pulse pressure readings performed during CMR (Fig. [2](#Fig2){ref-type="fig"}) \[[@CR20]\]. Aortic arch pulse wave velocity (PWV) was calculated as the distance around the arch between the ascending and descending aorta positions in the axial slice, divided by the time delay for arrival of the pulse pressure wave between these positions (Fig. [3](#Fig3){ref-type="fig"}) \[[@CR21]\]. The distance around the arch was assessed from an oblique sagittal view, and the time delay was calculated using cross-correlation of the flow velocity profiles generated by the velocity-encoded acquisition (Fig. [3a, d](#Fig3){ref-type="fig"}).Fig. 3Study participant flowchart

Statistical analysis {#Sec11}
--------------------

Continuous data were tested for normality and summarized using mean ± SD or median \[25th, 75th percentile\]. Differences between groups were determined using the Mann-Whitney or t-test as appropriate. Categorical data were expressed as counts and percentages and analysed by the Chi-squared test. Continuous variables with right-skewed distributions were logarithmically transformed prior to applying Pearson's test to assess relationships between continuous variables. The Benjamini and Hochberg procedure constrained the study-wise false discovery rate to a two-sided significance of 0.05 with adjusted *P* values presented \[[@CR22]\]. SPSS version 21.0 was used for all analyses.

Results {#Sec12}
=======

The participant flowchart is in Fig. [3](#Fig3){ref-type="fig"}. Eighty-three participants were studied; 54 patients within 6 months of commencing HD and 29 age- and sex-matched healthy volunteers. The causes of end-stage renal disease in HD patients were diabetes mellitus 17 % (14/54); glomerulonephritis 8 % (7/54); interstitial nephritis 7 % (6/54); vasculitis 5 % (4/54); polycystic kidney disease 4 % (3/54); ischemic nephropathy or malignant hypertension 7 % (6/54); light chain deposition disorder 5 % (4/54) and unknown or others 12 % (10/54). Subject characteristics and CMR findings are presented in Table [2](#Tab2){ref-type="table"}. The groups were well matched for age, sex, body mass index, body surface area, and smoking status. Most HD patients were treated for hypertension (78 %, 42/54) and 26 % (14/54) were treated with a renin-angiotensin-aldosterone system antagonist.Table 2Subject characteristics and CMR parametersHD (n = 54)Controls (n = 29)*p* value Age (years)57 ± 1556 ± 170.7 Female (%)15 (28)8 (28)1Anthropometric variables Body mass index (kg/m^2^)28 ± 627 ± 30.5 Body surface area(m^2^)1.9 ± 0.21.9 ± 0.20.9Medical history Time since commenced HD (days)94 ± 84 Diabetes mellitus (%)14 (26)2 (7) Ischaemic heart disease (%)13 (24)0 (0) Current/ex-smoker (%)25 (46)8 (28) Peripheral vascular disease/stroke (%)7 (13)0 (0) LV systolic dysfunction (%)4 (7)0 (0)Medication Treated hypertension (%)42 (78)2 (7) RAAS antagonist (%)14 (26)1 (3) Beta blocker (%)19 (35)0 (0) Other antihypertensive (%)37 (69)2 (7) Statin use (%)23 (43)4 (14)CMR parameters Global peak systolic strain (%)15.9 ± 3.719.3 ± 3.4\<0.001 Basal peak systolic strain (%)14.5 ± 3.818.4 ± 4.5\<0.001 Mid-ventricular peak systolic strain(%)16.2 ± 420 ± 4.2\<0.001 Apical peak systolic strain (%)16.9 ± 4.119.7 ± 3.40.002 Peak diastolic strain rate (s^-1^)1.07 ± 0.331.31 ± 0.380.003 Peak systolic strain rate (s^-1^)1.03 ± 0.221.28 ± 0.240.006 LV dyssynchrony by SD-TTP (ms)56 ± 2139 ± 14\<0.001 LV end-diastolic volume index (ml/m^2^)\*88 ± 2375 ± 140.002 LV stroke volume index (ml/m^2^)\*44 ± 1244 ± 90.8 LV ejection fraction (%)51 ± 1059 ± 5\<0.001 LV mass index(g/m^2^)\*63 \[54, 79\]46 \[42, 53\]\<0.001 LV mass/volume ratio (g/ml)0.76 \[0.64, 0.86\]0.65 \[0.55, 0.71\]0.001 Aortic distensibility (mmHg^−1^ × 10^−3^)2 \[1.3, 3.1\]4.1 \[3.1, 6.2\]\<0.001 Aortic pulse wave velocity (m/s)7.9 ± 3.55.3 ± 1.90.03 Systolic blood pressure (mmHg)143 ± 27139 ± 180.6 Diastolic blood pressure (mmHg)76 ± 1280 ± 100.2 Pulse pressure (mmHg)61 \[50, 79\]60 \[48, 68\]0.3Categorical data are displayed as counts (percentages). Continuous data were tested for normality and summarized as mean ± SD or median \[25th, 75th percentile\]. HD, haemodialysis; LV, left ventricular; RAAS, renin-angiotensin aldosterone system; SD-TTP standard deviation of time-to-peak strain.\*Values indexed to body surface area.

Image quality {#Sec13}
-------------

Eight HD patients did not tolerate long breath-holds and were managed by minimising the field of view and increasing the lines per segment to allow a breath-hold less than 15 seconds. Only 1 HD patient had significant arrhythmia which was managed by increasing the arrhythmia rejection window and prospective ECG gating. All cases were of diagnostic quality as assessed by an experienced CMR operator.

Global systolic and diastolic function {#Sec14}
--------------------------------------

Global LV systolic function was reduced in HD patients both by EF and PSS (EF 51.5 % ±11.0 in HD patients versus 58.5 % ±5.4 in control subjects, *p* \< 0.001; PSS 15.9 % ±3.7 versus 19.5 % ±3.3, *p* \< 0.001). Systolic function by global PSS was inversely correlated to LV dyssynchrony (r = -0.51, *p* \< 0.001), concentric remodelling (r = -0.37, *p* = 0.005) and troponin-T (r = -0.41, *p* = 0.03). Diastolic function was reduced in HD patients (PDSR 1.07 ± 0.33 s^-1^ in HD patients versus 1.31 ± 0.38 s^-1^ in control subjects, *p* = 0.003). Diastolic function was inversely correlated to LV dyssynchrony (r = -0.51, *p* \< 0.001), concentric remodelling, aortic PWV (r = -0.48, *p* = 0.04) and age (r = -0.31, *p* = 0.02).

LV mass and geometry {#Sec15}
--------------------

LV mass was increased in HD patients, (63 \[54, 79\] versus 46 \[42, 53\] g/m^2^, *p* \< 0.001) with greater LV concentric remodelling (LV mass/volume ratio 0.76 \[0.64, 0.86\] versus 0.65 \[0.55, 0.71\], *p* = 0.001, Table [2](#Tab2){ref-type="table"}).

Regional heterogeneity of LV strain {#Sec16}
-----------------------------------

Systolic function by PSS was significantly reduced in basal, mid-cavity and apical short-axis slices in HD patients compared to NCs (Table [2](#Tab2){ref-type="table"}). Significant regional reductions in PSS in HD patients were seen in 7 of 16 LV segments, particularly in the septal and lateral walls (Table [3](#Tab3){ref-type="table"} and Fig. [4](#Fig4){ref-type="fig"})Table 3Comparisons of regional peak systolic strain (%) using the 16 segment model of the left ventricle. Values are mean ± SDLV segment numberLV segment nameHDNC*p* value1Basal Anterior13.7 ± 5.715.1 ± 5.80.32Basal Antero-septal9.6 ± 5.213.5 ± 4.80.0013Basal Infero-septal11.3 ± 5.112.2 ± 4.70.44Basal Inferior14.7 ± 6.816.8 ± 5.40.25Basal Infero-lateral20.6 ± 6.824.5 ± 5.80.016Basal Antero-Lateral18.5 ± 5.622.5 ± 5.60.0037Mid Anterior18.8 ± 5.621.6 ± 4.30.028Mid Antero-septal14.3 ± 5.518.0 ± 4.50.0039Mid Infero-septal13.3 ± 5.218.0 ± 3.5\<0.00110Mid Inferior17.4 ± 6.420.0 ± 4.90.0511Mid Infero-lateral23.3 ± 6.424.4 ± 3.50.412Mid Antero-Lateral19.3 ± 4.921.4 ± 3.80.0513Apical Anterior17.5 ± 4.918.6 ± 4.20.314Apical Septal14.7 ± 5.318.0 ± 4.10.00315Apical Inferior17.9 ± 6.420.4 ± 6.70.0716Apical Lateral20.2 ± 5.420.7 ± 4.80.6Segments with significantly lower PSS in HD patients compared to age-matched controls are graphically highlightedFig. 4Comparisons of regional PSS using the 16-segment model of the left ventricle. Segments with significantly lower PSS in HD patients compared to age-matched controls are graphically highlighted

LV dyssynchrony {#Sec17}
---------------

There was greater LV dyssynchrony in HD patients as determined by increased dispersion in the time to peak strain (SD-TTP 56 ± 21 ms vs 39 ± 14 ms, *p* \< 0.001, Table [2](#Tab2){ref-type="table"}). LV dyssynchrony was inversely correlated to diastolic function by PDSR (r = -0.51, *p* \< 0.001) and EF (-0.45, *p* = 0.001; Table [4](#Tab4){ref-type="table"}).Table 4Correlation coefficients of systolic strain, diastolic strain-rate, LV dyssynchrony and aortic distensibility to potential determinants in HD patientsCMR ParameterPSSPDSRSD-TTPAortic distensibilityr-value*p* valuer-value*p* valuer-value*p* valuer-value*p* value Peak diastolic strain rate0.56\<0.001\-\--0.51\<0.0010.30.1 LV dyssynchrony by SD-TTP-0.51\<0.001-0.51\<0.001\-\--0.250.2 LV ejection fraction0.54\<0.0010.340.01-0.450.0010.220.3 Global peak systolic strain rate0.53\<0.0010.6\<0.001-0.350.010.430.02 LV mass index-0.190.2-0.10.50.180.2-0.240.2 LV end-diastolic volume Index0.020.90.140.30.100.50.100.6 LV mass/volume ratio (g/ml)-0.370.005-0.300.030.190.2-0.420.02 Global peak systolic strain\--0.56\<0.001-0.51\<0.0010.370.05 Aortic distensibility^§^0.370.0470.30.1-0.250.2\-- Aortic pulse wave velocity0.010.9-0.480.040.270.3-0.690.001Biochemical markers High-sensitivity troponin-T^§^-0.410.03-0.180.40.370.06-0.530.004 NT-Pro-BNP^§^-0.200.2-0.260.080.040.8-0.150.4Demographic variables Age-0.240.08-0.310.020.070.6-0.73\<0.001Anthropometric variables Body mass index-0.120.40.050.7-0.080.6-0.090.6 Body surface area-0.240.080.030.80.240.09-0.060.8 ECW/TBW^§^-0.260.1-0.180.3-0.030.8-0.280.2^§^Log-transformed data

Aortic distensibility {#Sec18}
---------------------

Aortic distensibility was decreased in HD patients (2.0 \[1.3, 3.1\] vs. 4.1 \[3.1, 6.2\], *p* \< 0.001) and correlated to PSS (r = 0.37, *p* = 0.047), PSSR (r = 0.43, p = 0.02), high-sensitivity troponin-T (r = -0.53, p = 0.004) and concentric remodelling (r = -0.42, p = 0.02, Table [4](#Tab4){ref-type="table"}). Aortic pulse wave velocity was increased in HD patients (7.9 ± 3.5 versus 5.3 ± 1.9 m/s, *p* \< 0.001).

Subgroup of HD patients with normal EF {#Sec19}
--------------------------------------

In the subset of HD patients with preserved EF \> 50 % (n = 35), aortic distensibility was still reduced (2.6 \[1.9, 4.8\] mmHg^−1^ × 10^−3^ versus 4.1 \[3.1, 6.2\] mmHg^−1^ × 10^−3^), LV mass remained increased (63 \[55, 79\] g/m^2^ versus 46 \[42, 53\] g/m^2^, *p* \< 0.001), PSS was reduced (17.5 ± 3.1 % versus 19.3 ± 3.4 %, *p* = 0.03), PDSR was reduced (1.10 \[0.83, 1.31\] s^-1^ versus 1.27 \[1.04, 1.41\] s^-1^, *p* = 0.03), and dyssynchrony remained greater (SD-TTP 51 ± 18 ms versus 39 ± 14 ms, *p* = 0.006; Table [5](#Tab5){ref-type="table"} and Fig. [5](#Fig5){ref-type="fig"}).Table 5Subject characteristics and CMR parameters stratified by EFControls with EF \> 50 % (n = 29)HD with EF \> 50 % (n = 35)*p* valueAge (years)55 ± 1656 ± 170.9Female (%)9(26%)8(28%)1Anthropometric variables Body Mass Index (kg/m^2^)28 ± 627 ± 30.4 Body surface area (m^2^)1.9 ± 0.21.9 ± 0.20.9 Extracellular water/Total body water ratio0.39 \[0.38, 0.40\]Medical history Time since commenced HD (days)98 ± 53 Diabetes mellitus (%)6 (17)2 (7) Ischaemic heart disease (%)9 (26)0 (0) Current/Ex-smoker (%)15 (43)8 (28) Peripheral vascular disease/Stroke (%)4 (11)0 (0) LV systolic dysfunction (%)3 (9)0 (0)Medication Treated hypertension (%)29 (83)2 (7) RAAS antagonist (%)12 (34)1 (3) Beta blocker (%)15 (43)0 (0) Other antihypertensive (%)25 (71)2 (7) Statin use (%)15 (43)4 (14)Biochemical markers High-sensitivity troponin-T ( μg/L)27 \[13, 54\] NT-pro-BNP (pg/ml)143 \[60, 513\]CMR parameters Global peak systolic strain (%)17.5 ± 3.119.3 ± 3.40.03 Basal peak systolic strain (%)16.2 ± 3.418.4 ± 4.50.04 Mid-ventricular peak systolic strain (%)18.0 ± 3.420.0 ± 4.20.05 Apical peak systolic strain (%)18.2 ± 3.919.7 ± 3.40.1 Peak diastolic strain rate (s^-1^)1.10 \[0.83, 1.31\]1.27 \[1.04, 1.41\]0.03 Peak systolic strain rate (s^-1^)-1.05 \[-1.23, -0.89\]-1.27 \[-1.40, -1.12\]\<0.001 LV dyssynchrony by SD-TTP (ms)51 ± 1839 ± 140.006 LV end-diastolic volume index (ml/m^2^)\*85 ± 2175 (14)0.04 LV stroke volume index (ml/m^2^)\*48 ± 1144 (9)0.2 LV ejection fraction (%)56 ± 559 (5)0.01 LV mass index(g/m^2^)\*63 \[55, 79\]46 \[42, 53\]\<0.001 LV mass/volume ratio (g/ml)0.77 \[0.68, 0.86\]0.65 \[0.55, 0.71\]\<0.001 Aortic distensibility (mmHg^−1^ × 10^−3^)2.6 \[1.9, 4.8\]4.1 \[3.1, 6.2\]0.04 Aortic pulse wave velocity (m/s)7.0 ± 3.65.3 ± 1.90.2 Systolic blood pressure (mmHg)137 ± 23139 ± 180.7 Diastolic blood pressure (mmHg)74 ± 1480 ± 100.08 Pulse pressure (mmHg)57 \[49, 76\]60 \[48, 68\]0.8Categorical data are displayed as counts (percentages). Continuous data were tested for normality and summarized as mean ± SD or median \[25th, 75th percentile\]. HD, hemodialysis; LV, left ventricular; RAAS, renin-angiotensin aldosterone system; SD-TTP, standard deviation of time-to-peak strain.\*Values indexed to body surface area.ECW/TBW extracellular water/total body water by bioimpedanceNT-pro-BNP N-Terminal Pro-B-type natriuretic peptideRAAS Renin-angiotensin aldosterone systemSD-TTP standard deviation of the segmental time to peak circumferential strainFig. 5Boxplots of Global PSS and LV dyssynchrony by SD-TTP stratified by EF

Subgroup of HD patients with diabetes, ischemic heart disease or LV dysfunction {#Sec20}
-------------------------------------------------------------------------------

To account for the confounding of pre-existing cardiovascular co-morbidities, we conducted subgroup analyses amongst HD patients categorised by presence or absence of diabetes, ischemic heart disease, prior LV dysfunction, and use of a beta-blocker or renin-angiotensin aldosterone system antagonist. These results are detailed in Supplemental Table [1](#Sec30){ref-type="sec"}. As adverse changes were notable amongst HD patients with diabetes, we compared CMR parameters in non-diabetic HD patients (n = 40) to non-diabetic controls (n = 27). Abnormalities such as reduced systolic strain, increased LV mass and reduced aortic distensibility remained apparent in HD patients without diabetes (Supplemental Table [2](#Sec30){ref-type="sec"}).

Discussion {#Sec21}
==========

We report the first study using tagged CMR in patients within 6 months of commencing HD, characterising abnormalities in cardiac size, geometry and strain in terms of magnitude, rate and synchronicity. The high prevalence of reduced systolic and diastolic strain (despite preserved EF), ventricular dyssynchrony, anteroseptal segmental dysfunction and reduced aortic distensibility was more evident with the detailed methods utilised. The relative lack of correlation between bioimpedance-measured volume status and LV strain was consistent with volume-independent mechanisms playing a role in the evolution of cardiac dysfunction in this setting.

These data support and extend previous CMR-based descriptions of cardiomyopathy in established HD patients. Separate reports characterised different aspects of cardiac and aortic function; however, such a comprehensive assessment in incident HD patients has rarely been reported. Mark and co-workers reported gadolinium contrast-enhanced CMR data in 134 prevalent HD or peritoneal dialysis patients selected for cardiovascular screening for potential renal transplantation. They reported a prevalence of 72 % for LV hypertrophy and 8.2 % for reduced EF, using cut-offs derived from published reference range studies. They also found heterogeneity in the distribution of focal myocardial fibrosis as determined by gadolinium-based contrast enhancement. The study was conducted prior to awareness of the association of gadolinium contrast media with nephrogenic systemic fibrosis and did not investigate strain or relationships to troponin-T. Their findings were concordant with our study, demonstrating lower EF and greater LV mass in HD patients with regional heterogeneity in strain. The differences between these prior studies and the present might be explained by differences in the populations studied and exposure to HD.

There are no prior studies of LV strain by CMR tagging in HD patients, which is currently the reference standard technique for LV deformation. This present study reports strain values for the age and sex-matched controls without kidney disease (19.5 ± 3.3 %) in keeping with reported reference ranges for circumferential strain by tagged CMR in healthy volunteers of 16--19 % \[[@CR23]\]. Strain values by tagged CMR may not be directly comparable to studies using tissue Doppler or speckle-tracking echocardiography. In general population studies, absolute differences of 10--25 % against a tagged CMR reference measure are reported, with wider disparities in disease states.

Ventricular morphology {#Sec22}
----------------------

Hypertrophy of the LV is an established feature of cardiomyopathy in HD patients, representing a maladaptive response that allows for normal EF despite abnormal pressure or volume load. In addition to traditional atherosclerotic risk factors, multiple factors are contributory, including aortic stiffness, volume and pressure overload, hyperphosphatemia and neurohormonal activation \[[@CR24]\]. Recent work has extended this picture with the implication of locally generated steroids and fibroblast growth factor 23, both of which are increased in HD patients \[[@CR25], [@CR26]\]. In particular, sodium can induce adrenal secretion of digitalis-like steroids to produce myocyte hypertrophy independent of blood pressure or volume effects, representing a novel mechanism linking dietary or dialysate sodium to LV hypertrophy in HD patients \[[@CR27]\]. In the present study, LV concentric remodelling by mass/volume ratio was significantly increased in HD patients compared to controls, even amongst those with preserved EF or without diabetes.

Heterogeneity of systolic strain {#Sec23}
--------------------------------

The regional heterogeneity of PSS has not previously been described in HD patients. In studies of hypertensive cardiomyopathy, tagged CMR demonstrated the earliest effects of pressure overload by basal septal reductions in PSS and PSSR \[[@CR28]\]. This is in contrast to infiltrative genetic disorders such as Fabry's disease where the earliest reductions in PSS are seen in inferolateral segments \[[@CR29]\]. The present study reports reductions in the entire septum, as well as anterolateral segments. This supports the notion that HD might be associated with a distinct cardiomyopathy, reflecting several remodelling signals, some of which are independent of pressure or volume, including recurrent HD ischemic insults \[[@CR24], [@CR30]\]. We observed significant correlations of PSS to LV dyssynchrony, concentric remodelling, aortic distensibility, aortic stiffness and high sensitivity troponin-T.

Diastolic function {#Sec24}
------------------

The determinants of diastolic function in HD patients are not well described, despite an increasing appreciation of the prognostic importance of this form of ventricular relaxation defect. Using speckle tracking echocardiography, De Bie and co-workers reported univariate determinants as LV mass, concentric remodelling and PWV \[[@CR31]\]. Losi and co-workers found a significant relationship of diastolic dysfunction in HD patients to echocardiographic-integrated backscatter (as a surrogate for myocardial fibrosis) \[[@CR32]\]. We additionally report significant relationships to LV dyssynchrony and age.

Synchronicity and coherence of ventricular contraction {#Sec25}
------------------------------------------------------

Synchronous contraction of the LV is essential to efficient cardiac output. LV dyssynchrony by tagged CMR has not previously been described in HD patients; in other settings, good reproducibility, preload independence and the ability to predict benefit from resynchronisation therapies have been demonstrated \[[@CR18], [@CR33]\]. El Ghannudi and co-workers reported SD-TTP of 28.5 ± 11.5 ms in control subjects and 91.3 ± 25 ms in patients with EF \< 55 % due to ischemic or dilated cardiomyopathy. This compares with 39 ± 14 ms in control subjects and 56 ± 21 ms in HD patients in the present study. LV dyssynchrony was positively correlated to PSS and inversely correlated to diastolic function by PDSR (r = -0.51, *p* \< 0.001) and EF (-0.45, p = 0.001). This study is the first to link LV dyssynchrony and diastolic dysfunction in HD patients.

Aortic distensibility {#Sec26}
---------------------

Aortic distensibility was reduced in HD patients and this pattern persisted in the subgroup of HD patients with preserved EF or without diabetes. Reported values are consistent with prior studies \[[@CR34]\]. In the present study, the strong correlation of aortic distensibility to troponin-T (r = -0.53, *p* = 0.004) is novel. Troponin-T reflects the presence and severity of HD-induced ischemia \[[@CR35]\], and is potentially aggravated by the increased risk of demand ischemia resulting from reduced aortic distensibility causing reduced diastolic coronary blood flow \[[@CR36]\]. Given that we examined an incident population which had been exposed to HD for a mean of 98 days, it is likely that the changes we saw in HD patients occurred, at least in part, prior to commencing HD. Edwards et al. compared aortic distensibility by CMR in patients with CKD stage 3 to normal controls \[[@CR37]\]. They derived similar values to the present study (2.2 ± 1.8 in CKD vs. 4.1 ± 1.3 mmHg^−1^ × 10^−3^ in controls) compared with 2.0 \[1.3, 3.1\] vs. 4.1 \[3.1, 6.2\] in the present study).

Volume status {#Sec27}
-------------

Biomarkers of volume status (ECW/TBW, LV end-diastolic volume index and NT-pro-BNP) showed no significant correlations to systolic strain, diastolic strain rate, LV dyssynchrony or aortic distensibility. This might indirectly represent volume-independent influences on cardiac function in HD patients.

Limitations {#Sec28}
-----------

Although we have examined associations, the cross-sectional design limits our ability to determine any causal relationships. In particular, a longitudinal study design would be a better design to assess the impact of HD on the natural history of cardiomyopathy. Circumferential strain is reported, but the lack of longitudinal strain is a limitation. Furthermore, we did not have a CKD or treated hypertension control group and, thus, cannot determine the extent of their relative contributions to the observed between group differences. This could be addressed by a longitudinal study design from early-stage CKD through to HD, but as most patients with CKD do not progress to end-stage kidney disease \[[@CR38]\], such a study would be prohibitively large. An alternative longitudinal studies amongst matched groups with hypertension, CKD and incident HD. Such a study might still have residual confounding that might not entirely be removed by statistical methods.

Conclusion {#Sec29}
==========

This study provides the first data comprehensively characterising LV strain, dyssynchrony and aortic distensibility by tagged CMR imaging in patients new to HD, revealing a greater degree of cardiac dysfunction than previously recognized. These abnormalities still persisted in HD patients with preserved EF or without diabetes. This reinforces the need to proactively engage in cardio-protective strategies and stresses the particular potential of dialysis therapy-based interventions.
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